Alliances
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval.
BioLineRx, based in Tel Aviv, Israel, and Merck & Co, based in Kenilworth, New Jersey, announced they are expanding their immuno-oncology collaboration.
Before taking over the helm of Novartis AG, Vasant Narasimhan pointed to the harnessing of digital technology as a key method of saving a significant percentage of clinical trial costs.
Since taking over the helm of GlaxoSmithKline, Emma Walmsley has been driving changes at the company with a heavy focus on pharma R&D. Today, Walmsley and R&D Head Hal Barron unveiled a long-term plan for R&D that is focused on the immune system and genetics.
South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.
Anima Biotech, based in Bernardsville, New Jersey, inked a discovery and development deal with Eli Lilly and Co. that has the potential to exceed $1 billion.
Shares of France’s TxCell S.A. have skyrocketed about 150 percent this morning after Sangamo Therapeutics announced it was acquiring a majority stake in the company for €72 million (about $82 million) in a cash deal.
BeiGene is starting off the week with a bang. Late Sunday the company announced positive preliminary topline results from its Phase II trial of tislelizumab, the company’s investigational checkpoint inhibitor for relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).
For many companies, artificial intelligence has become a key tool in drug development. Now, two companies that specialize in AI-backed drug development are teaming up to take on the rare disease known as Duchene Muscular Dystrophy.
Boston-based PureTech Health inked a multi-year collaboration deal with Swiss-based Roche to advance PureTech’s milk-derived exosome platform technology for oral dosing of Roche’s antisense oligonucleotide platform.
PRESS RELEASES